Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip

Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip
复制标题

通过蛋白质芯片分析糖尿病肾病的尿液蛋白质组模式

DOI:
10.1002/prca.200780083
复制
发表时间:
2008-05-01
影响因子:
2
通讯作者:
Chen, Yi-Ding
Chen, Yi-Ding
中科院分区:
生物学3区
文献类型:
--
作者:
Gu, Wei;Zou, Li-Xia;Chen, Yi-Ding

文献摘要

被引文献

相似文献

糖尿病肾病(diabetic nephropathy,DN)是糖尿病患者死亡的主要原因。本研究的目的是建立一种蛋白质组学的方法来检测尿中的蛋白质或肽,以识别早期DN的个体。我们收集了106例糖尿病患者和50例健康受试者的尿液样本。DN早期定义为尿白蛋白/肌酐比值在30 ~ 299 mg/g。使用表面增强激光解吸/电离飞行时间质谱法生成质谱。通过Ciphergen SELDI软件版本3.1检测峰。使用ProteinChip获得了超过1000种蛋白质或肽。其中约200个样品的m/z值在1008.5 ~ 79942.3Da之间,糖尿病组与对照组间差异显著。数学分析显示,糖尿病患者中有8个蛋白质表达上调,16个蛋白质表达下调,m/z值在2197.3 ~ 79613 Da之间,其中4个蛋白质表达上调最高,m/z值分别为4139.0,4453.5,5281.1和5898.5Da。结果表明,这些指纹图谱对早期糖尿病肾病的诊断敏感性为75%,特异性为80%。蛋白质芯片技术可能是一种新的无创检测早期DN的方法。
Diabetic nephropathy (DN) is the main cause of mortality for diabetic patients. The objective of this work was to develop a proteomic approach to detect proteins or peptides in urine for identifying individuals in the early stage of DN. We obtained urine samples from 106 diabetic patients and 50 healthy subjects. Early stage of DN was defined as urine albumin-to-creatinine ratio between 30 to 299 mg/g. Mass spectra were generated using surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry. Peaks were detected by Ciphergen SELDI software version 3.1. Over 1000 proteins or peptides were obtained using ProteinChip. About 200 of them, the m/z values were in the range from 1008.5 to 79 942.3 Da. These values were significantly differentiated between diabetic patients and control subjects. A mathematical analysis revealed that a cluster of 8 up-regulated proteins and 16 down-regulated proteins was in the diabetic patients, with m/z values from 2197.3 to 79 613 Da. Four top-ranked proteins, with m/z values of 4139.0, 4453.5, 5281.1, and 5898.5 Da, were selected as the potential fingerprints for detection of early stage DN with a sensitivity of 75% and a specificity of 80%. ProteinChip technology may be a novel non-invasive method for detecting early stage DN.